TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03619551
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Randomization between low and medium doses of busulfan for TCR αβ+/CD19+ depleted haploidentical related and unrelated donor HCT.
Study: NCT02119676
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg tablets to be administered by mouth~Ruxolitinib 20 mg twice a day (BID) (Part 1) (NOTE: The starting dose for the randomized portion of study (Part 2) was 15 mg BID based on results from Part 1.)
Study: NCT02119676
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160mg once daily for the first 21 days of each 28-day cycle. (NOTE: Dose interruptions and modifications for regorafenib are expected when toxicities occur in which dose interruptions or modifications are appropriate.)
Study: NCT01947907
Drug: ACP-001
Normalized name: ethanol
DrugBank: AP-001 (DB18511)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once weekly subcutaneous injection
Study: NCT01947907
Drug: Human Growth Hormone
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily subcutaneous injection of human Growth Hormone
Study: NCT00004190
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004190
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05288907
Drug: Lidocaine Ointment
Normalized name: Lidocaine Ointment
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite over-the-counter lidocaine ointment administered twice daily for 2 weeks.
Study: NCT01382147
Drug: Ara-C, Mitoxantrone, Daunorubicin, Thioguanin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT00811642
Drug: Posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400mg BID oral suspension for 12 weeks
Study: NCT02104388
Drug: Vehicle of SJP-0035 Ophthalmic Solution
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01935882
Drug: Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01935882
Drug: Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01465685
Drug: 3,4-Methylenedioxymethamphetamine
Normalized name: 3,4-Methylenedioxymethamphetamine
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg per os, single dose
Study: NCT01465685
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 hour before MDMA/placebo 60 mg methylphenidate per os, single dose
Study: NCT00171470
Drug: Tegaserod
Normalized name: Tegaserod
DrugBank: Tegaserod (DB01079)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01264328
Drug: Panitumumab + paclitaxel
Normalized name: Panitumumab
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m2 may be infused, intravenously, over one hour every week. Panitumumab will be administered every 2 weeks at a dose of 6 mg/kg, using a non pyrogenic low protein binding filter with a 0.20-0.22-μm pore size intravenously over 1 hour ± 15 minutes. Panitumumab will be administered prior to paclitaxel.
Study: NCT02617446
Drug: Istaroxime
Normalized name: Istaroxime
DrugBank: Istaroxime (DB06157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of 0.5 µg/kg/min or 1.0 µg/kg/min istaroxime
Study: NCT03030638
Drug: Olodaterol
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug
Study: NCT01330017
Drug: Phenylephrine HCl
Normalized name: Phenylephrine HCl
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-mg immediate-release tablets, orally, up to 4 tablets per dose every 4 hours, for 7 days
Study: NCT01330017
Drug: Loratadine
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-mg tablets, orally, once per day at a dose not to exceed 10 mg in a 24-hour period.
Study: NCT00362180
Drug: mipomersen
Normalized name: Mipomersen
DrugBank: Mipomersen (DB05528)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg subcutaneous injections
Study: NCT03030638
Drug: Indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug
Study: NCT02286726
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03785652
Drug: LY03005 extended-release tablets 80 mg group
Normalized name: hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LY03005 extended-release tablets 80 mg group :~80mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast
Study: NCT02032823
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be administred olaparib orally twice daily (b.i.d.) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
Study: NCT03914625
Drug: Asparaginase Erwinia chrysanthemi
Normalized name: Asparaginase Erwinia chrysanthemi
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV or IM
Study: NCT03914625
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT or IV
Study: NCT03914625
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT01666067
Drug: vytorin
Normalized name: Vytorin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03802214
Drug: Vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: standard vedolizumab induction (300mg IV at week 0, 2, 6)
Study: NCT00042341
Drug: clofarabine (IV formulation)
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00796887
Drug: Extended-Release Niacin
Normalized name: niacin Extended Release Oral Capsule
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg tablet once daily
Study: NCT00796887
Drug: Extended-Release Niacin
Normalized name: niacin Extended Release Oral Capsule
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg tablet once daily
Study: NCT03914625
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or IM
Study: NCT03914625
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO or IV
Study: NCT03914625
Drug: Thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03914625
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03428217
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral receptor tyrosine kinase inhibitor
Study: NCT03381742
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ticagrelor 45 mg twice daily for 5 consecutive days at least.
Study: NCT03381742
Drug: ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ticagrelor 90 mg once daily for 5 consecutive days at least.
Study: NCT03381742
Drug: ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ticagrelor 90 mg twice daily for 5 consecutive days at least.
Study: NCT03381742
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: clopidogrel 75 mg once daily for 5 consecutive days at least.
Study: NCT04066192
Drug: Brexpiprazole
Normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brexpiprazole will be used in .5mg, 1mg, 2mg, and 4mg doses as described in the study arms.
Study: NCT04300959
Drug: Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine:1000mg/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8； Anlotinib : 10mg po qd, days 1-14; Sintilimab: 200mg IV, day 1；~1 cycle = 3 weeks.
Study: NCT04300959
Drug: Gemcitabine Plus(+)Cisplatin
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine:1g/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8；~1 cycle = 3 weeks.
Study: NCT02099071
Drug: ACT-389949 1 mg
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02099071
Drug: ACT-389949 5 mg
Normalized name: sodium fluoride 0.5 MG/ML [ACT Fluoride Rinse]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02099071
Drug: ACT-389949 20 mg
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02099071
Drug: ACT-389949 50 mg
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02099071
Drug: ACT-389949 100 mg
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02099071
Drug: ACT-389949 200 mg
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02099071
Drug: ACT-389949 500 mg
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02099071
Drug: ACT-389949 1000 mg
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02609932
Drug: Administration of drug (Interferon-gamma 1-b) subcutaneously
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SD = group who has received a single dose of IFN-gamma (10, 25, 50, and 100 mcg/m2) given once with subsequent analysis of effects (serum IL-10, Neuropterin, and IFN levels as well as neutrophil Nox2 activity and gene expression by Affimetrics Chip analysis). One month is allowed between doses. SS = administration of four doses (50 mcg/m2) of IFN-gamma given on Monday, Wednesday Friday schedule with neutrophil or monocyte function studies performed before the first and after the fourth dose to determine steady state effects.
Study: NCT05477472
Drug: St John's Wort
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily intake of CERES St John's Wort mother tincture. Dose according to the treating physician.
Study: NCT00348933
Drug: Betaine
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100-200 mg per kg per day by mouth with a maximum of 6 grams divided in two daily doses
Study: NCT00348933
Drug: Metafolin
DrugBank: Levomefolic acid (DB11256)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg per kg per day by mouth with a maximum of 8 milligrams divided in two daily doses
Study: NCT00348933
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg by mouth per day for all weights and ages
Study: NCT01889095
Drug: BIAsp 30
Normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
Study: NCT01889095
Drug: NPH/Reg
Normalized name: INSULIN HUMAN 50/50 (NPH/REG) INJ
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
Study: NCT02984072
Drug: Menthol
Normalized name: Menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical menthol in aqueous cream
Study: NCT00950339
Drug: omeprazole, 20mg twice daily
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity
Study: NCT01220128
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
Study: NCT01220128
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously in Cohort C Groups in 6 doses at 3 weeks apart, on the same day as WT1 ASCI/placebo administration (Day 1 of each cycle).
Study: NCT01220128
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
Study: NCT01220128
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
Study: NCT01220128
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: only in the 8 WT1 ASCI-dose schedule patients received 4 at 3 weeks apart or 12 weekly doses. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
Study: NCT01220128
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously in Cohort C Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
Study: NCT00950339
Drug: famotidine 40mg twice daily
Normalized name: famotidine 40 MG
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity
Study: NCT00950339
Drug: pantoprazole 40mg once daily
Normalized name: lisinopril
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity
Study: NCT01350609
Drug: Nifedipine/Candesartan (BAY 98-7106)
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed dose combination of 60 mg nifedipine + 32 mg candesartan (1 tablet in one period)
Study: NCT01350609
Drug: Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)
Normalized name: atenolol and nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loose combination of 1 tablet nifedpipine 60mg (Adalat LA) and 2 tablets candesartan 16mg (Atacand) (3 tablets in one period) .
Study: NCT04117958
Drug: AMG 199
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 199 is a BiTE® molecule designed to direct T cells towards MUC17-expressing cells.
Study: NCT03416153
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC=1 weekly during radiation therapy. Carboplatin will be given once a week in combination with paclitaxel (standard treatment), concurrent with radiation therapy. Given IV.
Study: NCT03416153
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30 mg/m2 weekly during radiation therapy. Paclitaxel will be given once a week in combination with carboplatin (standard treatment), concurrent with radiation therapy. Given IV.
Study: NCT02467270
Drug: Ponatinib
Normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, taken orally once daily.
Study: NCT00797316
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aliskiren 150 mg or 300 mg taken once daily in oral form
Study: NCT00797316
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 mg or 25 mg taken once daily in oral form.
Study: NCT01892020
Drug: biphasic insulin aspart 50
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
Study: NCT01892020
Drug: biphasic human insulin 50
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
Study: NCT00227734
Drug: capecitabine and oxaliplatin + cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: cetuximab
Study: NCT00972140
Drug: Formoterol
Normalized name: Formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol-HFA pMDI 12µg twice daily
Study: NCT00972140
Drug: Formoterol
Normalized name: Formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol-DPI 12 µg twice daily
Study: NCT04318145
Drug: PL-3994 Aqueous Intravenous Solution Dose Ascention
Normalized name: PL-3994
DrugBank: PL-3994 (DB15355)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion
Study: NCT03078192
Drug: GE-141, Hyperpolarized 129Xenon gas
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XeMRI scans will provide 3D images of ventilation and gas exchange. Subjects will inhale HP 129Xe from the dose delivery bags. Then the subject will be moved into the scanner and they will undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will under-go several MRI scans after inhalation of HPXe
Study: NCT04000529
Drug: TNO155
Normalized name: SHP2 inhibitor TNO155
DrugBank: Batoprotafib (DB19137)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT04000529
Drug: Spartalizumab
Normalized name: Spartalizumab
DrugBank: Spartalizumab (DB14892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrate for solution for infusion
Study: NCT04000529
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsule and tablet
Study: NCT04318145
Drug: PL-3994 Aqueous Intravenous Solution Single Dose
Normalized name: PL-3994
DrugBank: PL-3994 (DB15355)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion
Study: NCT00649311
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan 50 mg oral capsule once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to losartan 100 mg oral capsule once daily for 4 weeks
Study: NCT04643301
Drug: Liraglutide Pen Injector
Normalized name: liraglutide Pen Injector
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily subcutaneous injection of 3.0mg liraglutide (GLP-1 antagonist) for low-responders 3 months after bariatric surgery.
Study: NCT01910311
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT04497961
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dose of 10mg oral lenalidomide on days 1-21 of each 28-day cycle.
Study: NCT01910311
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally